Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO – Get Rating) – Investment analysts at Northland Capmk issued their Q2 2023 earnings estimates for Cardio Diagnostics in a research note issued on Monday, May 22nd. Northland Capmk analyst C. Byrnes forecasts that the company will post earnings per share of ($0.21) for the quarter. The consensus estimate for Cardio Diagnostics’ current full-year earnings is ($0.75) per share. Northland Capmk also issued estimates for Cardio Diagnostics’ Q3 2023 earnings at ($0.21) EPS, Q4 2023 earnings at ($0.21) EPS, FY2023 earnings at ($0.75) EPS, FY2024 earnings at ($0.75) EPS, FY2025 earnings at ($0.70) EPS and FY2026 earnings at ($0.55) EPS.
Separately, Northland Securities assumed coverage on shares of Cardio Diagnostics in a report on Monday. They issued an “outperform” rating for the company.
Cardio Diagnostics Stock Up 19.7 %
Institutional Inflows and Outflows
A number of hedge funds have recently modified their holdings of CDIO. Susquehanna International Group LLP purchased a new position in shares of Cardio Diagnostics during the 4th quarter worth approximately $26,000. Bank of America Corp DE purchased a new position in shares of Cardio Diagnostics during the 1st quarter worth approximately $59,000. State Street Corp purchased a new position in shares of Cardio Diagnostics during the 1st quarter worth approximately $163,000. Finally, Geode Capital Management LLC purchased a new position in shares of Cardio Diagnostics during the 1st quarter worth approximately $290,000. 77.29% of the stock is owned by hedge funds and other institutional investors.
About Cardio Diagnostics
Cardio Diagnostics Holdings, Inc, a biotechnology company, develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks. The company was founded in 2017 and is headquartered in Chicago, Illinois.
- Get a free copy of the StockNews.com research report on Cardio Diagnostics (CDIO)
- Ralph Lauren’s Styled Dividend Is Still In Season
- Dollar Tree Falls As Theft Cuts Into Bottom Line
- Best Buy’s Comeback Is Still At Play, Earnings Call For Patience
- e.l.f. Beauty Has Giant Quarter, Shares Hit New High
- If You Can Only Pick One Stock For The Rest Of 2023, Pick Nvidia
Receive News & Ratings for Cardio Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardio Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.